KeyBanc last night downgraded Harvard Bioscience (HBIO) to Sector Weight from Overweight without a price target Despite the successful launch of the company’s new products such as the MeshMEA organoid platform and a turnaround strategy that continues to take shape, financing risk and an outsized academic market exposure are likely to weigh on shares of Harvard Bioscience over the near-term, the analyst tells investors in a research note. The firm adds that Harvard is currently operating under a waiver from its lenders, following the violation of a consolidated net leverage ratio covenant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Harvard Bioscience downgraded to Sector Weight from Overweight at KeyBanc
- Harvard Bioscience price target lowered to $4.50 from $5.50 at Benchmark
- Harvard Bioscience Reports 2024 Financial Results
- Harvard Bioscience Navigates Growth Amid Challenges
- Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year